Compare
Moderna, Inc. vs Exelixis, Inc. vs Halozyme Therapeutics, Inc. vs Neurocrine Biosciences Inc
| Latest fiscal year | Moderna, Inc. MRNA | Exelixis, Inc. EXEL | Halozyme Therapeutics, Inc. HALO | Neurocrine Biosciences Inc NBIX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-01-02 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.94B | $2.32B | $1.40B | $2.86B |
| Revenue growth (YoY) | -39.9% | +7.0% | +37.6% | +21.4% |
| Gross margin | 55.3% (computed) | n/a | 83.6% (computed) | n/a |
| Operating margin | -158.1% | 37.6% | 33.6% | 21.6% |
| Net margin | -145.2% | 33.7% | 22.7% | 16.7% |
| Net income | -$2.82B | $782.57M | $316.89M | $478.60M |
| EPS (Diluted) | -$7.26 | $2.78 | $2.56 | $4.67 |
| Operating cash flow | -$1.87B | $884.27M | $651.56M | $782.70M |
| Free cash flow | -$2.06B | $875.84M | $644.59M | $748.70M |
| Cash & equivalents | $2.60B | $482.49M | $133.82M | $713.00M |
| Total assets | $12.34B | $2.84B | $2.53B | $4.63B |
| Total liabilities | $3.69B | $683.10M | $2.48B | $1.38B |
| Shareholders' equity | $8.65B | $2.16B | $48.81M | $3.25B |
| Return on year-end equity | -32.6% | 36.2% | 649.2% | 14.7% |
| Shares outstanding | 394.00M | 262.48M | 117.78M | 100.10M |
Revenue, most recent five fiscal years
| Fiscal year | Moderna, Inc. | Exelixis, Inc. | Halozyme Therapeutics, Inc. | Neurocrine Biosciences Inc |
|---|---|---|---|---|
| Latest | $1.94B Ended 2025-12-31 | $2.32B Ended 2026-01-02 | $1.40B Ended 2025-12-31 | $2.86B Ended 2025-12-31 |
| 1 year earlier | $3.24B Ended 2024-12-31 | $2.17B Ended 2025-01-03 | $1.02B Ended 2024-12-31 | $2.36B Ended 2024-12-31 |
| 2 years earlier | $6.85B Ended 2023-12-31 | $1.83B Ended 2023-12-29 | $829.25M Ended 2023-12-31 | $1.89B Ended 2023-12-31 |
| 3 years earlier | $19.26B Ended 2022-12-31 | $1.61B Ended 2022-12-30 | $660.12M Ended 2022-12-31 | $1.49B Ended 2022-12-31 |
| 4 years earlier | $18.47B Ended 2021-12-31 | $1.43B Ended 2021-12-31 | $443.31M Ended 2021-12-31 | $1.13B Ended 2021-12-31 |